Qureight secures £1.5m seed funding led by Playfair Capital to advance complex disease platform
Playfair Capital led the seed investment in Qureight, with backing from Meltwind, Ascension, and Cambridge Angels, to accelerate drug development partnerships.
Share allotment filed at Companies House
Cambridge-based Qureight builds artificial intelligence tools to support pharmaceutical companies running clinical trials for respiratory and cardiovascular diseases.
Qureight has secured £1.5m in a seed follow on investment led by Playfair Capital, with participation from Meltwind, Ascension, and Cambridge Angels. The fresh capital will be deployed to accelerate drug development programmes in partnership with biopharma companies targeting pulmonary hypertension and adverse drug effects in complex lung cancer patients.
Founded by medical specialists, the Cambridge company develops platform technology that analyses CT scans and clinical data to generate digital biomarkers. This approach aims to reduce the costs and patient cohorts required for pharmaceutical trials in complex conditions such as idiopathic pulmonary fibrosis.
From the founder
"our next targets are pulmonary hypertension and adverse drug effects in complex lung cancer patients. This funding will allow us to use our platform to work with our biopharma partners to accelerate drug development in these areas."
Alessandro Ruggiero
Co-founder at Qureight
Investor perspective
"The world-leading clinical expertise of co- founders Dr Thillai and Dr Ruggiero has been crucial in Qureight’s development of the world’s only AI- powered platform dedicated to complex diseases."
Jeevan Sunner
Principal, Playfair
Use of funds
- 01Continue product development
- 02Fund research and development
